Biotech Values

[DewDiligence]

Does MNTA engage in spin? Yes, of course they do, albeit on a smaller scale than most biotech companies, IMO. An instance in which I think MNTA’s is spinning is where Craig Wheeler says the District Court’s consolidation of the NVS/MNTA and MYL Copaxone cases is not a setback for MNTA. I respectfully disagree.

At a minimum, the consolidation has delayed the start of the Copaxone trial by several months. It has also delayed the Judge’s ruling on the NVS/MNTA Markman hearing that took place in Jan 2010, which doesn’t really affect MNTA itself but does affect MNTA investors.

The most consequential downside of the consolidation, IMO, is that it may indicate that the Judge is unreceptive to NVS/MNTA’s argument for non-infringement, which is one of the four legal tacks Wheeler said NVS/MNTA intend to pursue in the Copaxone trial (#msg-56147443).

Comments?